MannKind Corporation Stock

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-05-17 EDT 5-day change 1st Jan Change
4.59 USD -0.22% Intraday chart for MannKind Corporation +6.25% +26.10%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 272M 371M Sales 2025 * 319M 434M Capitalization 1.25B 1.7B
Net income 2024 * 35M 47.64M Net income 2025 * 70M 95.27M EV / Sales 2024 * 3.68 x
Net cash position 2024 * 248M 338M Net cash position 2025 * 273M 371M EV / Sales 2025 * 3.07 x
P/E ratio 2024 *
39.9 x
P/E ratio 2025 *
20.9 x
Employees 413
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.51%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05 MT
Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, vs. Street Est of $60.6M MT
MannKind Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
MannKind Receives FDA Fast Track Designation for its Potential Lung Disease Treatment MT
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease CI
MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases CI
MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment MT
MannKind Gets FDA Clearance for Clofazimine IND Application DJ
MannKind Corporation Announces IND Clearance from U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial Lung Disease CI
MannKind CFO Binder to Retire in April, Names New CFO MT
MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024 CI
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects CI
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps CI
Transcript : MannKind Corporation, Q4 2023 Earnings Call, Feb 27, 2024
More news
1 day-0.22%
1 week+6.25%
Current month+11.68%
1 month+9.81%
3 months+25.75%
6 months+20.79%
Current year+26.10%
More quotes
1 week
4.40
Extreme 4.4
4.65
1 month
4.06
Extreme 4.06
4.65
Current year
3.17
Extreme 3.17
5.40
1 year
3.17
Extreme 3.17
5.75
3 years
2.49
Extreme 2.49
5.75
5 years
0.80
Extreme 0.8
6.25
10 years
0.67
Extreme 0.6662
57.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 16-03-13
Chief Tech/Sci/R&D Officer 57 22-09-30
Chief Tech/Sci/R&D Officer - 20-08-30
Members of the board TitleAgeSince
Director/Board Member 55 18-11-26
Director/Board Member 69 19-12-31
Director/Board Member 80 03-09-30
More insiders
Date Price Change Volume
24-05-17 4.59 0.00% 2,119,507
24-05-16 4.59 +3.15% 2,453,178
24-05-15 4.45 -1.11% 2,000,461
24-05-14 4.5 +2.04% 2,009,498
24-05-13 4.41 +2.08% 1,806,229

Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm

More quotes
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.59 USD
Average target price
7.083 USD
Spread / Average Target
+54.32%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW